

# The Canadian Journal of Neurological Sciences

# Le Journal Canadien des Sciences Neurologiques

- MR Spectroscopy of Temperature Effects in Brain Ischemia 317
- Cerebral Vasospasm and Lipid Peroxidation 326
- Headache: A Population Survey 333
- Treatment of Myasthenia Gravis 360
- Complete Table of Contents i



XXVIIIth Canadian Congress of  
Neurological Sciences  
June 16-19, 1993  
Toronto, Ontario


## The Official Journal of

The Canadian Neurological Society  
The Canadian Neurosurgical Society  
The Canadian Society of Clinical Neurophysiologists  
The Canadian Association for Child Neurology

Volume 19, No. 3

August 1992





# To a parkinsonian patient, a little help means a lot.

Adding Parlodel to levodopa can improve symptom control. Because you want to help your patient get more out of life's little pleasures.

Add

**PARLODEL**<sup>®</sup>   
(bromocriptine mesylate)

Because quality of life  
is the issue.

 **SANDOZ**

Sandoz Canada Inc.  
P.O. Box 385  
Dorval, Quebec  
H9R 4P5



For brief prescribing  
information see page xx





## Table of Contents

### ARTICLES

Magnetic Resonance Imaging and <sup>31</sup> P Magnetic Resonance Spectroscopy Study of the Effect of Temperature on Ischemic Brain Injury <i>Garnette R. Sutherland, Howard Lesiuk, Paul Hazendonk, James Peeling, Richard Buist, Piotr Kozlowski, Andrzej Jazinski and John K. Saunders</i> .....	317
Malondialdehyde, Glutathione Peroxidase, and Superoxide Dismutase in Cerebrospinal Fluid During Cerebral Vasospasm in Monkeys <i>R. Loch Macdonald, Bryce K.A. Weir, Tim D. Runzer and Michael G.A. Grace</i> .....	326
A Canadian Population Survey on the Clinical, Epidemiologic and Societal Impact of Migraine and Tension-Type Headache <i>William Pryse-Phillips, Helen Findlay, Peter Tugwell, John Edmeads, T.J. Murray and R.F. Nelson</i> .....	333
Comparison of the Efficacy and Safety of Flunarizine to Propranolol in the Prophylaxis of Migraine <i>M.J. Gawel, J. Kreeft, R.F. Nelson, D. Simard and W.S. Arnott</i> .....	340
The Distinctive Clinical Features of Paraneoplastic Sensory Neuropathy <i>Colin H. Chalk, Anthony J. Windebank, David W. Kimmel and Philip G. McManis</i> .....	346
Ventricular Size, Cognitive Function and Depression in Patients with Multiple Sclerosis <i>Campbell M. Clark, Gerald James, David Li, Joel Oger, Donald Paty and Harry Klonoff</i> .....	352
Amyotrophic Lateral Sclerosis: Interleukin-6 Levels in Cerebrospinal Fluid <i>Charles Krieger, Thomas L. Perry and Hermann J. Ziltener</i> .....	357
Treatment of Acquired Autoimmune Myasthenia Gravis: a Topic Review <i>Pradeep Verma and Joël Oger</i> .....	360
MRI Diagnosis of Brainstem Cavernous Angiomas Presenting as Tumours <i>Mark C. Preul, Jean-Guy Villemure, Richard Leblanc and Raquel del Carpio-O'Donovan</i> .....	376
Stiff-Person Syndrome <i>Mandar S. Jog, Colin D. Lambert and Anthony E. Lang</i> .....	383
Spontaneous Disappearance of an Intracranial Aneurysm After Subarachnoid Hemorrhage <i>Mark G. Hamilton and Oliver N.R. Dold</i> .....	389
Intraventricular Central Neurocytoma <i>M. Giroux, J.P. Farmer, K.M. Meagher-Villemure, A.M. O'Gorman and J.L. Montes</i> .....	392
John G. Humphrey – A Remembrance (1928-1991) <i>John Wherrett</i> .....	397
Neurocritical Care – Highlights from Two Austrian Meetings, December 1991 <i>G.B. Young and C.F. Bolton</i> .....	398
<b>ABSTRACTS</b> .....	
Abstracts of the 31st Annual Meeting of the Canadian Association of Neuropathologists .....	402
<b>BOOKS RECEIVED</b> .....	412
<b>BOOK REVIEWS</b> .....	413
<b>NOTES AND ANNOUNCEMENTS</b> .....	415
<b>CALENDAR OF EVENTS</b> .....	416
<b>SPECIAL AWARDS</b> .....	417
<b>INSTRUCTIONS TO AUTHORS</b> .....	vi
<b>ADVERTISERS INDEX</b> .....	xxvi



**Editor/Rédacteur en chef** James A. Sharpe *Toronto*  
**Associate Editors/Rédacteurs associés** Laurence E. Becker *Toronto*  
John Girvin *London* Terry Picton *Ottawa*  
**Past Editors** Robert G. Lee *Calgary*  
Robert T. Ross (founding editor) *Winnipeg*

**Editorial Board/Conseil Scientifique**

Peter Ashby <i>Toronto</i>	Peter Humphreys <i>Ottawa</i>
Warren Blume <i>London</i>	Richard Leblanc <i>Montréal</i>
Jean-Pierre Bouchard <i>Québec</i>	George Karpati <i>Montréal</i>
Donald Calne <i>Vancouver</i>	Patrick McGeer <i>Vancouver</i>
Peter Camfield <i>Halifax</i>	Richard Riopelle <i>Kingston</i>
Pierre Duquette <i>Montréal</i>	Richard Stein <i>Edmonton</i>
George Ebers <i>London</i>	John Stewart <i>Montréal</i>
Serge Gauthier <i>Montréal</i>	Charles Tator <i>Toronto</i>

**Book Review Editor/Rédacteur de critiques de livres** Mary Anne Lee *Calgary*  
**News Editor/Rédacteur (nouvelles)** John Norris *Toronto*  
**Managing Editor/Administratrice adjointe** Sally A. Gregg *Calgary*

**Publications Committee/Comité de Rédaction**

William F. Brown <i>London</i>	Warren Blume <i>London</i>
Gary Ferguson <i>London</i>	Frances Booth <i>Winnipeg</i>

**The Official Journal of:/La Revue Officielle de:**

**The Canadian Neurological Society**  
**La Société Canadienne de Neurologie**  
President/Président — C.W. McCormick  
Secretary-Treasurer/ — O. Suchowersky  
Secrétaire-Trésorier

**The Canadian Society of Clinical Neurophysiologists**  
**La Société Canadienne de Neurophysiologie Clinique**  
President/Président — Bryan Young  
Secretary-Treasurer/ — Michael Jones  
Secrétaire-Trésorier

**The Canadian Neurosurgical Society**  
**La Société Canadienne de Neurochirurgie**  
President/Président — H.J. Hoffman  
Secretary-Treasurer/ — Renn Holness  
Secrétaire-Trésorier

**The Canadian Association for Child Neurology**  
**L'Association Canadienne de Neurologie Pédiatrique**  
President/Président — Shashi Seshia  
Secretary-Treasurer/ — William Logan  
Secrétaire-Trésorier

The permanent secretariat for the 4 societies and the Canadian Congress of Neurological Sciences is at/  
Le secrétariat des 4 associations et du Congrès Canadien des Sciences Neurologiques est situé en permanence à:  
810, 906 - 12 Avenue S.W., Calgary, AB Canada T2R 1K7

The Canadian Journal of Neurological Sciences is published quarterly. The annual subscription rate is \$60 for members; \$70 for non-members in Canada; \$80 for USA and elsewhere. Residents, Interns, Pre- and Post-Doctoral Students \$30 per annum (members); \$40 per annum (non-members). Single copies \$18 each plus postage and handling. All manuscripts and communications should be sent to: Canadian Journal of Neurological Sciences, P.O. Box 4220, Station C, Calgary, AB Canada T2T 5N1. Courier to: 8th Floor, 906 - 12th Avenue S.W., Calgary, AB Canada T2R 1K7. Telephone (403) 229-9575.

COPYRIGHT© 1992 by THE CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES INC. No part of this journal may be reproduced in any form without the prior permission of The Canadian Journal of Neurological Sciences. Mailed under Publications Mail registration number 3307. Postage paid at Calgary, Alberta. This journal is indexed by *Index Medicus*, *Excerpta Medica* and *Current Contents — Clinical Practice and Life Sciences*.

Le Journal Canadien des Sciences Neurologiques est publié trimestriellement. L'abonnement annuel est de 60 \$ pour les membres; 70 \$ pour les non-membres au Canada; 80 \$ pour les Etats Unis et ailleurs. Internes, résidents, fellows pré et post doctoral: 30 \$ par année (membres); 40 \$ par année (non-membres). Copie simple: 18 \$ plus affranchissement et manutention. Toutes les communications et les manuscrits doivent être adressés à Journal Canadien des Sciences Neurologiques, P.O. Box 4220, Station C, Calgary, AB Canada T2T 5N1. Par courrier: 8th Floor, 906 - 12th Avenue S.W., Calgary, AB Canada T2R 1K7. Téléphone (403) 229-9575.

DROITS D'AUTEUR© 1992: THE CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES INC. Aucune partie de ce Journal ne peut être reproduite, sous quelque forme que ce soit, sans la l'autorisation du Journal Canadien des Sciences Neurologiques. Posté sous permis de poste-publications no 3307. Port payé à Calgary, Alberta. Le Journal est cité et indexé dans *Index Medicus*, *Excerpta Medica* et *Current Contents — Clinical Practice et Life Sciences*.

**Advertising representative/Représentant de publicité** Sally Gregg, Canadian Journal of Neurological Sciences  
810, 906 - 12 Ave. S.W., Calgary, AB Canada T2R 1K7 — (403)-229-9575

**Printer/Imprimeur** McAra Printing Limited, 105, 2507 - 12th Street N.E., Calgary, Alberta T2E 7L5

ISSN 0317 - 1671



UN PRODUIT  
DE LA  
RECHERCHE  
INNOVATRICE  
HOECHST

# Frisium<sup>®</sup> 10 mg

(clobazam)

ANTICONVULSIVANT COMME TRAITEMENT ADJUVANT

## EFFICACITÉ

- **Frisium** est efficace contre tous les types de crises épileptiques, tant chez les enfants que chez les adultes.<sup>1</sup>
- Avec **Frisium**, les patients réfractaires peuvent atteindre une maîtrise complète dans jusqu'à 30 % des cas, et cela compte tenu du type de crises.<sup>1</sup>

## INNOCUITÉ

- Les effets secondaires sont généralement bénins et passagers.<sup>2</sup>
- Sur le plan clinique, les interactions médicamenteuses significatives sont rares.
- L'altération de la vigilance est moins prononcée avec **Frisium** qu'avec les autres benzodiazépines.\*

## POSOLOGIE

- Une dose quotidienne allant jusqu'à 30 mg peut être prise en une seule fois au coucher.

DANS L'ÉPILEPSIE

*ajoutez*

# Frisium<sup>®</sup> 10 mg

(clobazam)

## POUR MAÎTRISER LES CRISES

CCPP

\* Voir la rubrique  
Précautions dans  
la monographie.



Hoechst et ®, Marques déposées Hoechst AG, Allemagne

Hoechst Canada Inc., Montréal H4R 1R6

**Hoechst**







# SIBELIUM.\* CHANGING THE FACE OF MIGRAINE PROPHYLAXIS.

Sibelium is changing the face of migraine prophylaxis by significantly reducing both the frequency and severity of attacks.<sup>1,2</sup> Seventy percent of patients can expect a good to excellent response.<sup>1</sup> As well, up to 41% will be completely migraine-free.<sup>2</sup>

Sibelium represents a new class of calcium antagonist indicated for migraine prophylaxis. Because of its unique cerebral selectivity<sup>3,4</sup>, Sibelium has not resulted in any reported effect on

heart rate, blood pressure or cardiac output.<sup>5,6</sup> Consequently, it is well tolerated by most patients; its most common side effects seldom result in discontinuation of therapy.<sup>3</sup> Further, Sibelium's convenient once daily dosage<sup>3</sup> enhances patient compliance.

If your migraine patients are candidates for prophylaxis, consider the efficacy of Sibelium. Uniquely selective, generally well-tolerated migraine prophylaxis.

once-a-day  
SIBELIUM<sup>®</sup>  
flunarizine

Pinpoint accuracy in migraine prophylaxis.






 JANSSEN  
PHARMACEUTICA  
Mississauga, Ontario  
\*Trademark

MEMBER  
PAAB  
CCPP  
PMAC

(v)


For brief prescribing information see page xviii

# Botulinum toxin information


	<b>Physicians that are injecting</b>
	<b>Reimbursement</b>
	<b>Training seminars</b>
	<b>Patient support groups</b>
	<b>Safety/efficacy profile</b>

## Call 1-800-44-BOTOX

This number provides you with the latest information on botulinum toxin and its use. Call today.



**Botulinum Toxin  
Type A**

 **ALLERGAN PHARMACEUTICALS** Allergan Pharmaceuticals, A Division of Allergan, Inc., Irvine, CA 92713

©1992 Allergan, Inc.



# IMPORTANT NEWS ABOUT THE USE OF ELDEPRYL.

Deprenyl Research and Purdue Frederick are pleased to announce that Eldepryl (selegiline hydrochloride) is now indicated for first line therapy in newly diagnosed patients with Parkinson's disease.

As you may know, Eldepryl first line has been shown to delay disability thereby prolonging functional life in early, untreated patients. In fact, Eldepryl can delay the onset of functional disability and the need for levodopa therapy by as much as one year.<sup>1,2</sup>


As well, there is increasing evidence that Eldepryl may have a neuroprotective effect.\*

Eldepryl also appears to have a remarkable safety profile. It has been generally well tolerated with few side effects.<sup>3,4,5</sup>

For all these reasons, it makes sense to start Eldepryl upon diagnosis and to continue therapy even if there is no obvious symptomatic improvement.

So for your parkinsonian patients, prescribe Eldepryl first line. It's their first line of defence against the progression of disability.

Yours truly,



Neil Mellor  
Product Manager

For your supply of new Patient Information Pads, please contact:  
Deprenyl Research Limited, Toronto, Ontario M6R 2M7.  
Telephone (416) 537-4372 Fax (416) 537-4087.

**ELDEPRYL<sup>®</sup> FIRST LINE**  
selegiline hydrochloride


\* Animal research findings suggest that selegiline may have a neuroprotective effect. It is not clear, however, how this relates to human parkinsonism and its treatment. **1** The Parkinson Study Group. Effect of Deprenyl on the Progression of Disability in Early Parkinson's Disease. *New Eng Journ* 321, November 1989, 1364-1371. **2** Tetrud JW, Langston JW. The Effect of Deprenyl (Selegiline) on the Natural History of Parkinson's Disease. *Science*, August 1989, vol. 245, 519-522. **3** Langston JW in Lees A. Deprenyl in Parkinson's Disease: Guidelines for Clinicians. *North American Round Table Series*, No. 1, 1988, 9-10. **4** DuVoisin RC in Lees A. Deprenyl in Parkinson's Disease: Guidelines for Clinicians. *North American Round Table Series*, No. 1, 1988, 10. **5** The Parkinson Study Group. Effect of Deprenyl on the Progression of Disability in Early Parkinson's Disease. *New Eng Journ* 321, November 1989, 1368.

PAAB

## NOW ELDEPRYL IS INDICATED FOR FIRST LINE THERAPY.

Now you can do more than deal with the disability of Parkinson's disease. You can delay it with Eldepryl first line. □ In newly diagnosed patients, Eldepryl can significantly retard the worsening of symptoms<sup>2,3</sup> and delay the need for levodopa therapy.<sup>2,4,5</sup> □ In fact, Eldepryl can delay the onset of disability and thereby prolong functional life by as much

as one year.<sup>1,4</sup> □ As well, Eldepryl appears to have a remarkable safety profile. It has been generally well-tolerated with few side effects.<sup>4,6,7</sup> □ So when you see patients with Parkinson's disease, prescribe



**HOLD BACK THE DISABILITY  
OF PARKINSON'S DISEASE  
FOR AN EXTRA YEAR.<sup>1</sup>**

Eldepryl first line. It's their first line of defence against the progression of disability.

**ELDEPRYL<sup>®</sup> FIRST LINE**  
selegiline hydrochloride

DELAYS THE PROGRESSION OF DISABILITY.

PAAB



Getting more reliable data for more confident evoked potential and electrophysiologic analyses is easy. All you need is the new Nicolet Spirit.<sup>™</sup>

### Reliable. Powerful. Complete.

Spirit gives you data quality like you've never seen before. Signal-to-noise ratio measurements quantify the amount of noise entering your data so waveform reliability is optimized. Powerful digital filtering with on-line and optional off-line functions further enhances the quality of the information.

Collect reliable data over long distances. Spirit makes it possible. Unique digital amplifiers, built into the headbox, minimize electrical interference so information remains accurate—even in a demanding operating room environment.

### Easy. Fast. Flexible.

Spirit handles your needs from diagnostic evoked potentials to operating room applications. Its multi-tasking capabilities, intuitive software, color-coded waveforms and more make operation easy...and fast.

Trust a leader in advanced diagnostic instruments to help you diagnose with more confidence. Trust Nicolet. With offices worldwide, we have a Nicolet representative in your area.

Call or write today for further information.

Nicolet Instruments Canada, Inc.  
1-1200 Aerowood Drive  
Mississauga, Ontario, L4W 2S7  
Canada Tel. 416-625-8302  
Toll free in Canada 1-800-387-3385

**Nicolet**  
INSTRUMENTS OF DISCOVERY




The Nicolet Spirit.<sup>™</sup>  
It brings new confidence to electrophysiologic analysis.





# Low-dose Prolopa. Benefits for the brain and the body.



The newest therapy recommendations for Parkinson's disease are to begin levodopa therapy at the lowest effective dose.

Not all levodopa combinations are formulated to be used at low doses.\* For example, the manufacturer of 100 levodopa/25 carbidopa (MSD) recommends the equivalent of 3 tablets per day<sup>1</sup> to reduce the incidence of nausea and vomiting so often associated with early levodopa therapy.<sup>1</sup>

## **Low-dose Prolopa (50/12.5). A unique levodopa formulation for few G.I. side effects.**

Prolopa uses a different peripheral decarboxylase inhibitor.<sup>1</sup> It allows you to start therapy with the lowest recommended levodopa dosage and a low incidence of nausea and vomiting.<sup>2</sup>

Consider initiating with Prolopa. For early Parkinson's control with a lower dose.

**PROLOPA<sup>®</sup>**  
**50/12.5**  
(levodopa 50 mg / benserazide 12.5 mg)

## Levodopa that starts lower.

\*Less than 300 mg of levodopa per day

PAAB

For brief prescribing information see page xxii





**Be Part of a  
Miracle!**

## **TRANSPLANTATION**

A proven, effective treatment for end-stage organ disease.

Through transplants, hundreds of Canadians have a chance of a normal, productive life.

But many others don't get that chance. They die waiting for donated kidneys, hearts, lungs and livers.

Ask the families of brain-injured patients about organ donation. It doesn't conflict with the interests of these patients. It can give the families a chance to change pain and death into life and hope.

### **Remember TRANSPLANTS WORK**

MORE Ont.	1-800-263-2833
PORT B.C.	1-800-663-6189
HOPE Alb.	(403) 492-1970
METRO Que.	(514) 876-6768
OPEN Newf.	(709) 737-6600
OPT-NB N.B.	(506) 648-6111
HSC Man.	(204) 787-2379

OD-91-04-1639E

ROY T.  
Kidney Transplant  
June 26, 1989



$$\begin{array}{r} 8652 \\ + 9496 \\ \hline 48 \end{array}$$



## Certains antiépileptiques peuvent réprimer plus que les crises.

Il arrive malheureusement que certains antiépileptiques tels la phénytoïne affaiblissent la fonction cognitive.<sup>(1,2,3,4)</sup>

D'autre part, Tegretol<sup>®</sup> CR (carbamazépine à libération contrôlée) a peu d'impact sur la fonction cognitive tout en procurant un excellent contrôle des crises.<sup>(1,2,3,4)</sup>

Tegretol CR réalise des taux sanguins plus uniformes que le Tegretol conventionnel, ce qui a pour effet de réduire la fréquence des effets secondaires intermittents et de

produire un modèle de fonction cognitive plus stable.<sup>(1,4)</sup>

Lorsque vous amorcez un traitement ou qu'il est médicalement nécessaire de le changer, pensez au Tegretol CR. Il est présenté en comprimés à 200 mg et 400 mg facilement divisibles pour une plus grande souplesse d'administration. Sa posologie à deux prises par jour seulement favorise l'observance du patient.

Tegretol CR - Parce qu'un antiépileptique ne doit pas affaiblir la capacité d'acquisition.



### TEGRETOL<sup>®</sup> CR.

*Aide les épileptiques à réaliser leur plein potentiel.*

(xiii)

PAAR  
1339  
G-90136F

Pour documentation voir pages xxi et xxii

**Gelgy**  
Mississauga, Ontario  
L5N 2W5




# Two landmark studies establish the superiority of ticlopidine in lowering the risk of recurrent stroke

## The first agent proven more effective than ASA in preventing initial stroke.

■ Ticlid (ticlopidine HCl) is a unique antiplatelet therapy that inhibits ADP-induced platelet-fibrinogen binding. Unlike ASA, Ticlid does not inhibit prostacyclin, thromboxane or prostaglandins.<sup>1</sup>

In the Ticlopidine Aspirin Stroke Study (TASS) involving 3,069 TIA and minor stroke patients, Ticlid was shown to reduce the risk of initial stroke by a considerable margin compared with ASA.<sup>2</sup>



TICLID REDUCED THE RISK 47.6% RELATIVE TO ASA IN THE FIRST YEAR ( $p=0.0004$ )<sup>3</sup>

“The benefit of ticlopidine was apparent early in the first year and persisted for the entire five years of follow-up.”

Ticlopidine Aspirin Stroke Study (TASS)  
New England Journal of Medicine 1989


## Proven effective in preventing recurrent stroke.

■ In the placebo-controlled Canadian American Ticlopidine Study (CATS), 1,072 patients who had experienced a recent thromboembolic stroke were treated and observed for up to 3 years.

Over the course of the study, Ticlid was shown to reduce the risk of non-cardiogenic stroke by 34%.<sup>4</sup>

“...the efficacy of ticlopidine was consistent and significant for both men and women.”

Canadian American Ticlopidine Study (CATS)  
The Lancet 1989



TICLID REDUCED THE RISK 34% RELATIVE TO PLACEBO OVER 3 YEARS<sup>4</sup>

## Proven safety profile

■ The most common side effects were generally mild, transient and occurred early in therapy.<sup>1</sup> Often they were resolved by a temporary dose reduction.<sup>2</sup>

In clinical trials, there was a reported 2.4% incidence of neutropenia (0.8% severe). Upon immediate discontinuation of therapy, the neutrophil count returned to normal within 1 - 3 weeks.<sup>1</sup>

To manage the risk of neutropenia, regular WBC monitoring is required every 2 weeks for the first 3 months of therapy.<sup>1</sup>



# Mark studies the efficacy of Ticlid in the risk of stroke.



“...the benefits of ticlopidine clearly outweigh the associated risks.”

Canadian American Ticlopidine Study (CATS)  
The Lancet 1989

# Ticlid®

The risk of stroke has never  
been lower.

TICLID IS INDICATED FOR PATIENTS WHO HAVE EXPERIENCED ANY OF THE FOLLOWING EVENTS:<sup>1</sup>

Transient Ischemic Attack (TIA)

Transient Monocular Blindness (TMB)

Reversible Ischemic Neurological Deficit (RIND)

Minor stroke (minimal deficit, >80% recovery)

Complete thromboembolic stroke

Blood monitoring is required every 2 weeks for the first 3 months of Ticlid therapy.

Dosage: 250 mg BID with meals

**For information on this unique stroke prevention therapy, call the Ticlid Information Hotline 1-800-263-8918.**

 SYNTEX®

For brief prescribing information see page xvii





## VALPROATE: THE GROWTH OF EXPERIENCE IN PRIMARY GENERALIZED EPILEPSY

For years, valproate has been regarded as an excellent choice for the control of absence seizures.<sup>1,2</sup>

In addition to its proven efficacy in simple and complex absence seizures,<sup>2,3</sup> valproate has been shown to be as effective as previous standards in controlling primary generalized seizures with tonic-clonic manifestations.<sup>4</sup> Epival\* tablets have a special enteric-coating designed to reduce GI upset<sup>5</sup> and are bioequivalent to Depakene\*.<sup>6</sup>

Compared to most antiepileptics, Epival has been shown to have minimal effects on behaviour and cognition<sup>7</sup> and relatively less interactions with commonly-prescribed medications.<sup>8,9</sup>

Today's consensus favours monotherapy wherever possible. And no other single agent can provide this spectrum of efficacy in the management of primary generalized seizures.<sup>1</sup>



**Epival\***  
divalproex sodium

HELPING TO MEET TODAY'S THERAPEUTIC GOALS

 PHARMACEUTICAL PRODUCTS DIVISION  
ABBOTT LABORATORIES, LIMITED  
MONTREAL, CANADA

\*TM © Abbott Laboratories, Limited

